NewAmsterdam Pharma Co. disclosed that Chief Operating Officer Douglas Kling resigned effective August 14, 2026, to become CEO of another clinical-stage biotech company. Unvested stock options and restricted stock units were canceled, except for those eligible to vest through May 14, 2027 contingent on his advisory services. Mr. Kling entered an Advisor Agreement providing transition support for the PREVAIL clinical trial of obicetrapib in exchange for a $50,000 monthly fee plus expenses until May 14, 2027. The company operates as a clinical-stage biopharmaceutical firm focused on developing treatments for metabolic and cardiovascular diseases.

NewAmsterdam Pharma Company N.V. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $64.1 million and revenue of $3.7 million. The company holds $678.3 million in cash, cash equivalents, and marketable securities. Clinically, NewAmsterdam received a positive CHMP opinion from the European Medicines Agency recommending marketing authorization for obicetrapib and its combination with ezetimibe for treating primary hypercholesterolemia or mixed dyslipidemia. The firm plans to announce an interim analysis of its Phase 3 PREVAIL cardiovascular outcomes trial in the fourth quarter of 2026, with results expected in the first quarter of 2027. Additionally, topline data from the Phase 3 RUBENS trial is anticipated by year-end 2026. NewAmsterdam Pharma Company N.V. operates as a late-stage biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.

Douglas Kling notified NewAmsterdam Pharma Company N.V. of his resignation as Chief Operating Officer, effective August 14, 2026, to become CEO of another clinical-stage biotech firm. The company expects to enter into a separation agreement and an advisor agreement with Mr. Kling to provide transition and advisory services regarding the PREVAIL clinical trial of obicetrapib and other clinical programs. Material terms of these agreements will be disclosed in a future amendment. NewAmsterdam Pharma is a clinical-stage biotechnology company.